Autolus Therapeutics (AUTL) Operating Leases (2019 - 2026)
Autolus Therapeutics' (AUTL) quarterly Operating Leases came in at $71.4 million in Q4 2025, up 35.64% YoY from $52.6 million in Q4 2024, and up 8.43% on a QoQ basis from $65.8 million in Q3 2025.
Autolus Therapeutics (AUTL) Operating Leases (2019 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 7 years of Operating Leases data on file, last reported at $71.4 million in Q4 2025.
- Quarterly Operating Leases rose 35.64% year-over-year to $71.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $71.4 million (up 35.64% YoY) and the FY2025 annual result came in at $71.4 million, up 35.64% from the prior year.
- Operating Leases advanced to $71.4 million in Q4 2025, from $65.8 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $71.4 million in Q4 2025 to a low of $11.3 million in Q3 2022.
- A 5-year average of $38.7 million and a median of $45.8 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2021 — Operating Leases tumbled 64.93% — and 2023, when it jumped 315.27%.
- Tracing AUTL's Operating Leases over 5 years: stood at $21.0 million in 2021, then advanced by 15.52% to $24.3 million in 2022, then soared by 118.37% to $53.0 million in 2023, then fell by 0.64% to $52.6 million in 2024, then soared by 35.64% to $71.4 million in 2025.
- The last three Operating Leases figures came in at $71.4 million (Q4 2025), $65.8 million (Q3 2025), and $64.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.51 Mn |
| Dec 31, 2025 | 71.39 Mn |
| Sep 30, 2025 | 65.84 Mn |
| Jun 30, 2025 | 64.54 Mn |
| Mar 31, 2025 | 57.71 Mn |
| Dec 31, 2024 | 52.63 Mn |
| Sep 30, 2024 | 52.23 Mn |
| Jun 30, 2024 | 50.02 Mn |
| Mar 31, 2024 | 51.34 Mn |
| Dec 31, 2023 | 52.97 Mn |
| Sep 30, 2023 | 46.97 Mn |
| Jun 30, 2023 | 44.71 Mn |
| Mar 31, 2023 | 22.50 Mn |
| Dec 31, 2022 | 24.26 Mn |
| Sep 30, 2022 | 11.31 Mn |
| Jun 30, 2022 | 13.21 Mn |
| Mar 31, 2022 | 15.08 Mn |
| Dec 31, 2021 | 21.00 Mn |
| Sep 30, 2021 | 17.34 Mn |
| Jun 30, 2021 | 18.79 Mn |